When Should Unmet Need Trump Inadequate Data?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Esbriet review exemplifies FDA’s eternal struggle between requiring adequate evidence of efficacy and giving patients with deadly diseases a chance at treatment.